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PAF-acether (PAF) is a newly formed mediator not normally present in circulating blood. A compound 
exhibiting all of its biological characteristics but coeluting with phosphatidylcholine (PC) in high-pressure 
liquid chromatography (HPLC) was unveiled (‘peak X’) in normal human plasma. A second HPLC run 
of peak X HPLC fractions revealed the presence of PAF itself with concomitant disappearance of peak 
X. Beside PAF, immunoreactive apolipoproteins A-I and E were found in peak X. Also lipoproteins (Ls) 
purified using either ultracentrifugation or immunoaffinity chromatography yielded peak X and, in a second 
HPLC run, authentic PAF. L-free plasma was devoid of peak X. Finally, after preincubation with plasma, 
labeled PAF was found associated with Ls. Thus in human blood preformed PAF is bound in high amounts 
to Ls, a result of interest given the role of Ls and platelets in vascular diseases and the present knowledge 
on PAF biosynthesis. 
PAF-acether; Lyso PAF-acether; Lipoprotein 
1. INTRODUCTION 
Since the discovery of PAF (formerly known as 
platelet-activating factor) [I], several of its 
biological and physico-chemical features have been 
unveiled [2,3]. PAF is one of the most potent 
newly-formed mediators released from and acting 
on most cells and organs that participate in inflam- 
matory diseases. It is an analog of phosphatidyl- 
Correspondence address: J. Benveniste, INSERM 
U 200, 32 rue des Carnets, 92140 Clamart, France 
Abbreviations: ADP, adenosine diphosphate; HDL, 
high density lipoprotein; HPLC, high-pressure liquid 
chromatography; LDL, low density lipoprotein; Ls, 
lipoproteins; PC, phosphatidylcholine; rt, retention 
time; VLDL, very low density lipoprotein 
choline [4], the molecular structure of which is 
I-0-alkyl-2-0-acetyl-sn-3-glycerophosphocholine 
[5,6]. In human subjects and experimental 
animals, the presence of PAF in blood has been 
reported only in pathological conditions [7-l I]. 
Indeed, when analyzing normal plasma from 
various mammalian species, we did not generally 
find - or we detected very low levels of - PAF. 
Yet, after lipid extraction and HPLC, we observed 
what appeared as a new molecular moiety of this 
mediator, exhibiting all of its characteristics 
[1,12-141. However, its retention time was 
unusual since it corresponded to that of PC. This 
unusual HPLC peak of platelet aggregating activi- 
ty (‘peak X’) has already been reported by our 
laboratory and other investigators but not 
characterized [11,15,16]. We thus examined the 
molecular constituents of peak X and its relation- 
ship with PAF. 
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2. MATERIALS AND METHODS 
2.1, Purification and characterization of Ls 
Plasma samples were obtained from 30 in- 
formed volunteers who had fasted for at least 
8-12 h. In a first set of experiments, Ls were 
isolated using either sequential preparative ultra- 
centrifugation, VLDL (d < 1.006 g/ml), LDL (d 
1.006-1.063 g/ml) and HDL (d 1.063-1.21 g/ml) 
[ 171, or an affinity column of goat anti-apoprotein 
B antibody coupled to Sepharose 4B [ 181. In the 
latter method, plasma (20 ml) was applied to the 
immunosorber. After the unretained fractions 
were eluted with PBS, pH 7.3, and the absorbance 
returned to the baseline, 3 M sodium thiocyanate 
(20 ml) followed by PBS, pH 7.3, was applied to 
the column to de&b the retained L containing 
apoprotein B (a mixture of LDL and VLDL). Ls 
obtained using both methods were dialyzed against 
0.15 M NaCl, pH 7.5, and submitted to the Folch 
extraction procedure [ 191. In some experiments, 
13H]PAF (1.06 pmol, Amersham, England, 
100 Ci/mmol) was incubated for 1 h at 4°C with 
3 ml of normal human plasma, which was then 
submitted to gradient ultracentrifugation [20]: 
VLDL (d < 1.017 g/ml); IDL (d 1.017-1.023 
g/ml); LDL (d 1.023-1.061 g/ml); intermediate 
fraction (d 1.061-1.070 g/ml); HDL (d 1.070- 
1.115 g/ml); proteins (d 1.115-l .253 g/ml). Each 
fraction was dialyzed against 0.15 M NaCl, pH 
7.5, to remove unbound PAF. Samples of protein 
fractions were assessed for radioactivity and pro- 
tein determination. Sandwich immunoassay for 
human apoproteins was performed as described 
using polyclonal antibodies against apoprotein A- 
I, A-II, B, C-III, E and a monoclonal antibody 
against apoprotein E [21]. 
2.2. HPLC of L fractions 
Human plasma (1 ml) was mixed with ethanol 
(4 ml) for 2 h at room temperature and then cen- 
trifuged at 900 x g for 15 min. The precipitate was 
discarded and the supernatant was dried. The dried 
residue or the L dried extracts from the Folch pro- 
cedure (see above) were dissolved in 500~1 of 
HPLC solvent (dichloromethane/methanol/water, 
400:333:50). In some experiments 5 nCi of L-3- 
phosphatidylcholine-l-stearoyl-2-[l-’4C]arachido- 
nyl (Amersham, 1 mCi/mmol was added to 
plasma immediately before ethanol extraction). 
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Samples were applied to a Microporasil column 
3.9 mm ID x 300 mm length (Waters Associates, 
Milford, MA), which was then eluted at a flow rate 
of 1 ml/min. PC, sphingomyelin, PAF and 
lysophosphatidylcholine were used as markers. 
1 ml fractions were analyzed by differential refrac- 
tometry, collected, dried and resuspended in 100 ,~l 
of 60% ethanol and then assayed for platelet ag- 
gregating activity. A sample of each fraction 
(100 ~1) was mixed with scintillation fluid for 
measurement of radioactivity. In some ex- 
periments, peak X fractions (11-13 min) from a 
first HPLC were pooled, dried and dissolved in 
80~0 ethanol and kept at room temperature for at 
least 7 days. The fraction pool was then dried and 
redissolved in the HPLC solvent system for a 
second HPLC run. In other experiments, the 
second run was performed using a reverse HPLC 
procedure. A Spherisorb c6 column was used with 
a fluid phase of 10 mM ammonium acetate, 
acetonitrile, methanol, 10: 45 : 45, at a flow rate of 
1 mb’min. Standards were Iabeled PAF and la- 
beled PC. 
2.3. Lyso PAF and PAF assay 
Fractions corresponding to peak X were submit- 
ted to chemical acetylation using acetic anhydride 
and pyridine [22]. Rabbit washed platelets were 
prepared as in [l ,131. Aspirinated platelets (1.6 x 
log) in Tyrode’s (300~1) containing 2.5% gelatin 
and the ADP scavenger mixture, creatine 
phosphate (1 mM)/creatine phosphokinase (10 
U/ml) were stirred in an aggregometer (Icare, 
Marseille, France). Aggregating activity of the 
samples before and after chemical acetylation was 
measured over the linear portion of the calibration 
curve obtained with 5 to 50 pg synthetic PAF. 
Other criteria for PAF (native or following 
chemical a~etylation) were used as detailed in sec- 
tion 3 below. 
3. RESULTS AND DISCUSSION 
Results are given as means f 1 SD. 
3.1. Presence of peak X and PAF in human blood 
and plasma 
The peak X (i.e. the aggregating activity eluted 
from standard phase HPLC with a rt similar to 
PC, 11-13 min) was observed in all ethanolic ex- 
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Fig. 1. HPLC (standard phase) elution profile of peak X 
and PAF-acether from plasma. One experiment 
representative of three. Arrows indicate the void volume 
(VdVOl) and the rt of phosphatidylcholine (PC), 
sphingomyelin (SpH), PAF-acether (PAF) and 
lysophosphatidylcholine (LPC). (Top) First HPLC run 
of plasma ethanolic extracts. (Bottom) Second HPLC 
run of peak X recovered from the first HPLC. 
[‘4C]Phosphatidylcholine was added to ethanolic 
extracts before HPLC. Detector esponse was monitored 
during HPLC and radioactivity and platelet aggregation 
in peak X 
were assessed on each HPLC fraction. 
Apart from its chromatographic behaviour, this 
substance appeared strictly undistinguishable from 
PAF itself, since it shared all of its known 
characteristics: (i) peak X, as well as PAF, induced 
aggregation of rabbit and human platelets 
pretreated with aspirin in the presence of the 
creatine phosphatejcreatine phosphokinase com- 
plex, thus ruling out the participation of 
arachidonic acid and ADP, respectively [13]. (ii) 
The aggregating activity - native or following 
acetylation - found in peak X was totally sup- 
pressed following treatment with phospholipase 
AZ, C and D but not with lipase from R. arrhizus 
[4]. (iii) Both peak X and PAF induced platelet 
desensitization to a second challenge by PAF, sug- 
gesting that the structural requirements for activity 
were the same for peak X as for PAF [12]. (iv) BN 
52021 (a gift from IPSEN-Beaufour, Le Plessis- 
Robinson, France), a specific antagonist of the 
PAF putative receptor [ 14,231, inhibited aggrega- 
tion induced by submaximal concentrations of 
peak X and PAF (50 pg/ml). The antagonist ICSO 
values were: 0.35 +- 0.19 and 0.45 f 0.23 PM (n = 
3) respectively. Using gas chromatography with 
electrocapture detection, the PAF isolated af- 
tracts from plasma and whole blood (fig.1, top). 
The aggregating activity in the peak X recovered 
from 1 ml of plasma (n = 4) or blood (n = 4) was 
19.46 f 10.30 and 9.37 + 2.19 ng, respectively. 
Given a hematocrit of around 0.4, the peak X ap- 
pears predominantly associated with the plasma. 
In some samples, we observed a platelet ag- 
gregating activity of fractions comigrating on 
HPLC with synthetic PAF (rt = 20-24 min). 
However, this activity was much lower than in 
peak X, i.e. 0.23 f 0.29 ng and 0.23 + 0.28 ng in 
fractions from 1 ml of blood and plasma, respec- 
tively. Lyso PAF, the deacetylated precur- 
sor/derivative of PAF, was present in peak X in 
high amounts: for 1 ml of plasma, 478.8 + 
91.0 ng, n = 3. 
When the PC-X peak was rechromatographed 
after prolonged storage in 80% ethanol, a PC peak 
devoid of aggregating activity was detected and a 
typical PAF activity peak with a rt of 20-24 min 
was now present (fig. 1, bottom). Labeled PC in- 
corporated in the starting plasma ethanolic extract 
co-chromatographed with the PC-X peak in the 
first and with the PC peak in the second HPLC run 
(fig. 1, top, bottom). Thus, the PAF-like activity 
present in the peak X could be dissociated from 
PC, yielding in the second HPLC run a substance 
that shared the same characteristics with authentic 
PAF. Furthermore, peak X migrated in reverse- 
phase HPLC with a rt between 42 and 52 min, 
whereas labeled PAF and PC were eluted at 5-14 
and 22-30 min, respectively. Taken together, 
these results show that peak X and PC, although 
comigrating in the first HPLC run, are different 
compounds. 
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ter the second HPLC run was identified as 
being mainly 1-0-hexadecyl-2-O-acetyl-sn-glycero- 
3-phosphocholine (not shown). 
3.3. Molecular composition of peak X 
The above results suggested that PAF was 
associated with a complex that modified its HPLC 
rt and that was dissociated in the second HPLC 
run. Ls, that bind phospholipids, were likely can- 
didates as PAF carrier. The sandwich enzyme- 
immunoassay for human apoproteins revealed 
some immunoreactivity of peak X with polyclonal 
anti A-I and E antibodies and monoclonal anti-E 
antibody. Thus peak X appeared to contain low 
amounts (about 5 ng/ml) of a material im- 
munoreactive with apolipoprotein A-I and E. In 
other words, peak X was a complex composed of 
apolipoproteins, PAF, lyso PAF and probably 
other unidentified lipids. This complex was not 
dissociated during extraction and during a first 
HPLC run. However, it is highly plausible that 
most of the apolipoproteins were denatured during 
organic extraction and HPLC explaining the low 
amount of proteins detected using the im- 
munoassay. 
We then recovered peak X following HPLC of 
plasma L, purified using either sequential 
preparative ultracentrifugation or immunoaffinity 
chromatography. Almost the same amount of 
peak X was present in LDL and HDL, whereas a 
small activity was measured in VLDL (table 1). A 
minute activity exhibiting the rt of PAF was also 
extracted from LDL and HDL. A second HPLC 
run of peak X from purified L again yielded a 
platelet aggregating activity with the typical rt and 
biological features of PAF. These experiments 
demonstrated that circulating Ls were a source of 
peak X that was dissociated to yield PAF itself in 
the second HPLC run. Another strong argument 
in favour of Ls was that in three experiments, 
plasmas freed from L by ultracentrifugation yield- 
ed 0.16 & 0.17 ng/ml of peak X (vs 19.46 t 10.30 
in 4 normal plasmas) and 0.07 1 + 0.12 ng/ml PAF 
(vs 0.23 + 0.28 in normal plasmas). This experi- 
ment again indicated a strong link between the 
presence of peak X and L, and ruled out serum 
albumin as a carrier for PAF in peak X, since the 
L-free plasmas contained a normal amount of 
albumin but yet practically neither peak X nor 
PAF activity was found. 
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Labeled PAF incubated with plasma at 4°C 
bound to protein fractions obtained by gradient 
ultracentrifugation (table 2). 24 and 65% of the 
radioactivity was recovered in the L fractions and 
in the fraction containing albumin and other 
plasma proteins, respectively. However, when 
these results are expressed in pg PAF bound per 
mg protein, preferential incorporation of the 
radioactivity is observed in Ls. In two preliminary 
experiments, it was investigated whether labeled 
PAF was incorporated either as such or as a 
metabolite. In the first experiment, one third of the 
radioactivity coeluted with the void volume, one 
third with peak X, and one third with PAF. In the 
other experiment, most of the label coeluted with 
lyso PAF (not shown). While this article was in 
preparation, binding of labeled PAF to lipopro- 
teins was reported [24]. 
The binding pattern of labeled PAF to plasma 
described above is reminiscent of the well- 
established binding of PAF to serum albumin [l]. 
The question thus arises whether the latter is also 
a circulatory carrier for PAF. The answer is 
negative since in several attempts we never 
recovered PAF from serum albumin either from 
Sephadex G-200-fractionated normal human 
serum or from commercial sources. Therefore, 
even if serum albumin does bind PAF, the en- 
dogenous PAF final distribution in the plasma is 
the result of a long-term equilibrium which 
depends on presently undefined factors. We know 
since many years that, if 2.5 mg serum albumin per 
ml of buffer allows for an optimal yield of PAF, 
raising this concentration to 25 mg/ml abolishes 
PAF recovery and, in parallel, inactivates ex- 
ogenously added PAF (Benveniste, unpublished). 
Therefore, physiological concentrations of 
albumin might help in controlling the level of free 
PAF in plasma but cannot act as a PAF carrier, a 
role which appears devoted to Ls. 
The latter finding is not surprising in view of the 
known capability of L to bind phospholipids. An 
interaction of PAF with HDL has been suggested 
since esterification of plasma cholesterol was in- 
hibited by PAF [25]. Yet, this report is the first to 
establish that L and especially LDL and HDL 
carry high amounts of a mediator that is con- 
sidered as a most potent agonist in inflammatory 
and shock states. Recovery of PAF from L is in ap- 
parent contradiction with the association to HDL 
Volume 226, number 2 FEBS LETTERS 
Table 1 
Peak X and PAF-acether in lipoprotein fractions (n = 3) 
Sequential ultracentrifugation 
LDL HDL VLDL 
Immunoaffinity 
chromatography 
Lipoproteins 
containing 
apoprotein B 
Peak X 3.43 f 1.79= 2.60 + 1.40 0.80 & 0.10 4.19 
PAF-acether 0.29 + 0.50 0.14 f 0.24 0 0 
a ng equivalent PAF-acether/mg protein 
Ls were isolated from plasma using either sequential ultracentrifugation [17] or 
affinity chromatography with Sepharose 4B-coupled anti-apoprotein B antibody [18]. 
Isolated Ls were then submitted to HPLC and platelet aggregation was assessed on 
fractions. Peak X and PAF-acether corresponded to rt 1 l-13 min and 20-24 min, 
respectively 
January 1988 
and LDL of the PAF catalytic enzyme, 
acetylhydrolase [24,26]. We lack information on 
the site(s) and the mode of incorporation of PAF 
into the lipoprotein complex. However, since we 
recovered both the intact molecule and its lyso 
precursor/derivative, we can hypothesize that: (i) 
PAF escapes hydrolysis when buried in the com- 
plex, most probably in a compartment separated 
from acetylhydrolase; and (ii) lyso PAF is either 
Table 2 
Incorporation of [3H]PAF-acether in plasma proteins 
(n = 4) 
Protein fractions Incorporated radioactivity 
(vo of total (pg bound/mg 
added) protein) 
VLDL 2.8 k 1.2 24.2 + 6.1 
IDL 1.5 + 0.4 33.1 + 20.3 
LDL 9.0 + 1.7 21.2 f 3.2 
Intermediate fraction 1.6 + 0.9 15.4 * 3.8 
HDL 10.8 + 1.1 9.5 + 1.5 
Proteins 65.0 f 14.0 1.1 f 0.2 
[3H]PAF-acether (1.06 pmol) was incubated with 
normal plasma (3 ml). Ls were obtained using gradient 
ultracentrifugation [20]. Radioactivity counts and 
protein determination were performed on L and protein 
fractions 
directly bound to the complex or results from the 
hydrolysis of part of the PAF within the complex. 
Whether the L PAF originates from the de novo or 
the remodeling pathway [2] remains to be in- 
vestigated. Nevertheless, binding of PAF to L may 
favour release of this mediator from cell sources, 
prevent its degradation by plasma acetylhydrolases 
and also influence the L/cell interactions. It is 
noteworthy that Ls which play a major role in 
atherosclerosis, carry a compound (PAF) that is 
capable both of suddenly increasing local vascular 
permeability and of powerfully attracting and ac- 
tivating platelets and polymorphonuclear leuco- 
cytes, i.e. the major cell participants in vascular 
lesions. 
In addition, these results might change our cur- 
rent view on PAF biosynthesis and release. PAF 
should now be considered both as newly-formed 
upon cell activation via classical biosynthetic 
pathways [2] and as a preformed circulating 
mediator. Preformed PAF is also bound to L in 
various cell types and organs in the form of peak 
X. We have recently performed clinical studies in- 
dicating that, in inflammatory states, it is man- 
datory to assess the amount of L PAF in the blood 
and biological fluids where free PAF is generally 
absent (Benveniste et al., to be published). It is 
clear from the present data that when PAF is ‘hid- 
den’ within the L complex, it cannot reach its 
molecular or cellular targets. However, should it 
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be liberated from its plasma or cellular carrier, a 
blood concentration of about 9 nM could be 
reached, thus causing severe intravascular lesions 
or even death. The presence in blood of high 
amounts of PAF bound to L and its potential 
release in pathological states might lead to recon- 
sider the pathophysiological role of this mediator, 
especially in acute and chronic vascular diseases. 
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